

Important Notice



The information contained in this presentation is for information purposes only. The information contained in this presentation is not investment or financial product advice and has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. To the extent permitted by law, no responsibility for any loss arising in any way from anyone acting or refraining from acting as a result of this information is accepted by Medibank Private Limited ("MPL") or any of its related bodies corporate. No representation or warranty, express or implied, is made by any person, including MPL, and its directors, officers, employees, professional advisors and agents ("Related Parties") as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation.

An investment in MPL securities is subject to investment and other known and unknown risks, some of which are beyond the control of MPL. MPL does not guarantee any particular rate of return or the performance of MPL securities.

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of MPL and associated entities of MPL entities and certain plans and objectives of the management of MPL. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "guidance", "forecasts", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of MPL to be materially different from the results or performance expressed or implied by such forward-looking statements.

Such forward-looking statements are based on numerous assumptions regarding MPL's present and future business strategies and the political, regulatory and economic environment in which MPL will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance.

No representation or warranty is made that any of these statements or forecasts (express or implied) will come to pass or that any forecast result will be achieved.

Forward-looking statements speak only as at the date of this presentation and to the full extent permitted by law, MPL, its affiliates, related bodies corporate and Related Parties disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

All figures in the presentation are A\$ unless stated otherwise and all market shares are estimates only. A number of figures, amounts, percentages, estimates, calculations of value and fractions are subject to the effect of rounding. Accordingly, the actual calculations of these figures may differ from figures set out in this presentation.


The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions. Nothing in this presentation constitutes an offer or invitation to issue or sell, or a recommendation to subscribe for or acquire securities in any jurisdiction where it is unlawful to do so. This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released, directly or indirectly, in the United States.

This presentation should be read in conjunction with MPL's other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au.

About Medibank

A leading private health insurer with a growing integrated healthcare business

PRIVATE HEALTH INSURANCE



DIVERSIFIED INSURANCE







INTEGRATED HEALTHCARE

POPULATION HEALTH

Garrison Health Services

WE DELIVER AN INTEGRATED HEALTHCARE SERVICE

60,000+ permanent 20,000+ reservist **Uniformed ADF personnel**



FROM INJURY OR ILLNESS





TELEHEALTH



- Support, coordination and navigation
- Mental health and counselling
- Triage
- After-hours and emergency

CHRONIC DISEASE MANAGEMENT



CareFirst | CarePoint | CareTransition For Better Health

Australian Health Insurance Industry

Challenges and opportunities in an evolving consumer landscape

CHALLENGES



Affordability



Health system complexity





Ageing and chronic disease

OPPORTUNITIES





Hospital substitution and reducing low value care



Transparency




Chronic disease management

For Better Health

Advocating for Regulatory Reform

Regulatory reform needed, but pace and extent of change less certain



BROADER REGULATORY LANDSCAPE



- Medicare Benefits Schedule Review
- Primary Healthcare Advisory Group
- Prosthesis List Advisory Committee
- Private Health Ministerial Advisory Committee
- Senate Inquiry into PHI



 Options paper for pricing and funding for safety and quality



Strategic Priorities

Unlocking Medibank's potential to drive growth and competitive positioning

Strong purpose - For Better Health

Deliver superior customer service

- Easy to deal with and enable channel of choice
- Employees empowered to help customers
- Trusted and reliable we do what we say we'll do
- Proactive and personalised engagement

Optimise our product suite

- Return value to our customers via product investments
- Insight led propositions that improve choice, flexibility and fit to customer needs
- Two brands focused on key segments, providing differentiation

Leverage our scale

- Utilise our unique data and insights
- Empower customers through data sharing
- Personalisation and predictive analytics
- Superior healthcare value – collaborative, partnership valuebased purchasing

Expand integrated care

- Leverage infrastructure and capabilities into new populations
- Prevention through health and wellness
- Substitution through in home care
- Support through healthcare concierging

Maintain strong financial position



Milestone Scorecard

Some early indicators of progress

CUSTOMER Objectives to reach by 2019 **Update** 1. PHIO complaints less than PHIO complaints reduced: market share (by December Sep-16 quarter: 61% share Dec-16 quarter: 48% share 2017 survey) 2. NPS best in class against NPS improved, but gap major private health to peers remains insurance peers1 Dec-16: down 36bps to 3. Market share stabilised 27.20% (from 30 June 2016)

FINANCIAL Objectives to reach by 2019 **Update** 1H17 FY16 I. Maintain operating margin² Medibank 7.7% 8.1% above major private health n/a³ 5.8% insurance peers¹ Major peers 1H17 FY16 2. Maintain ROE above cost of capital and major listed Medibank 28.7% 27.6% insurance peers4 Major peers 10.3% 14.3% 3. More than double Complementary 1H17: 6.5% Services share of segment FY16: 4.6% operating profit from FY16

- Bupa, HCF and nib
- 2 Australian residents only
- nib 1H17 operating margin 8.8%. Bupa and HCF not available.
- 4 nib, AMP, IAG and QBE. 1H17 ROEs are annualised

Customer Reorientation

Improvements in customer service, product value and transparency, but still more to be done

IMPROVED PRODUCT VALUE

- New products well received
 - Medibank's Core and Complete Hospital
 - ahm's Boost range
- Medibank 2017 premium rate rise 24bps below industry average

IMPROVED CUSTOMER SERVICE

- Upgraded customer website and mobile app launched in April 2017
- Average speed of answer (ASA) down nearly 30% to below 4 minutes despite a 15% increase in call volumes (3Q17 vs. 3Q16)

IMPROVED TRANSPARENCY

- Access to information to help choose a medical specialist (Healthshare)
- Creating a seamless and transparent healthcare experience for customers (Medipass)
- Ongoing simplification of customer communications






MEMBER SERVICES PORTAL LOAD TIME

72%







Technology Improvement

On track for new IT system to soon move out of hyper-care as planned

- Clearer priorities and stronger governance across business
 - Navigated through premium review period for the first time on the new platform
 - Good progress in Tax Statement preparation
- Embedding of new IT system (DelPHI) remains on track
 - Significant reduction in DelPHI-related incidents
 - Expect to move out of hyper-care within the next three months as planned



• Greater stability of technology is visible through improving customer experience



Healthcare Initiatives

Helping to drive better outcomes for our customers

- Continued momentum in CareComplete
 now reached 10,000 participants
- Providing customers with the information they need to make informed decisions – Health Concierge
- Delivering in-home care to our customers – rehab, chemo and palliative care in the home
- Collaborative value-based purchasing with providers – e.g. St John of God



1H17 Result Summary

Operating result reflects increased investment in customer initiatives

GROUP \$231.9m

HEALTH INSURANCE OPERATING PROFIT

\$249.4m

INTERIM DIVIDEND

5.25cps

- Group net profit after tax (NPAT) \$231.9m, up 1.9% from \$227.6m in 1H16
- Underlying NPAT of \$219.4m, up 1.8% from \$215.5m in 1H16
- Health Insurance: 8.2% decrease in operating profit to \$249.4m from \$271.7m in 1H16, reflecting increased investment in customer initiatives, new IT system amortisation and moderately higher growth in utilisation rates
 - Premium revenue of \$3,117.9m, up 1.2%
 - Gross margin of 16.9%, down from 17.2% in 1H16
 - Management expense ratio of 8.9%, compared to 8.4% in 1H16
 - Operating margin of 8.0%, down from 8.8% in 1H16
- Complementary Services: 88.0% increase in operating profit to \$17.3m reflects divestments in 1H16
- Net investment income: \$76.8m, up from \$18.6m in 1H16 due to higher equity market returns and stronger credit markets
- Interim dividend of 5.25 cents per ordinary share fully franked

Outlook

Full year operating profit guidance reaffirmed

- Health Insurance operating profit for FY17 expected to be approximately \$490 million
- Short term focus remains to further strengthen the core. Investment in the customer will continue, funded from internal productivity gains where possible
- Customer experience, value and outcomes are all improving, but it will take time to turn around the historical market share trajectory
- Expanding our customer offer will gain more focus later in 2017



Q&A

Glossary

Term	Definition
1H	Six months ended/ending 31 December of the relevant financial year
2H	Six months ended/ending 30 June of the relevant financial year
1Q	Three months ended/ending 30 September of the relevant financial year
2Q	Three months ended/ending 31 December of the relevant financial year
3Q	Three months ended/ending 31 March of the relevant financial year
bps	Basis points (1.0% = 100 bps)
CY	12 months ended 31 December 20XX

Term	Definition
FY	Financial year ended/ending 30 June 20XX
MPL	Medibank Private Limited
NPAT	Net profit after tax
NPS	Net promoter score
PHI	Private health insurance
PHIO	Private Health Insurance Ombudsman
ROE	Return on equity
Underlying NPAT	Underlying NPAT is calculated based on statutory NPAT adjusted for short-term outcomes that are expected to normalise over the medium to longer term, most notably in relation to the level of gains or losses from equity investments, and for one-off items, especially those that are non-cash, such as asset impairments

